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Abstract In order to map the immunogenic epitope for the produced mainly by activated monocytes-macrophages, was 
monoclonal antibody E7H2 on the human turnout necrosis factor initially characterized as a protein inducing the haemorrhagic 
(hTNF-~) molecule, a number of chimeric proteins were necrosis of certain transplanted tumours in mice [7]. To date, 
developed by in-frame joining segments of the human genes TNF-c~ has been proved to be a key mediator of inflammation 
encoding TNF-c~ and lymphotoxin (TNF-[3) as well as by during infectious diseases and exerts strong system effects in- 
coupling appropriate coding regions for human and mouse cluding the septic shock [8]. In an attempt o gain more in- 
TNF-c~. High level expression of these chimeric genes was sight into the functional topography of the TNF-~ molecule, 
achieved in Escherichia coli by placing the coding sequences we initiated an epitope analysis using monoclonal antibodies 
under control of either E. coli trp-promoter or a tandem of (Mabs) E7H2 [9] which are specific for human recombinant 
bacteriophage T7 constitutive promoters A2 and A3. As revealed TNF-~ [10]. Here, we report the construction of chimeric and 
by Western blot analysis with monoclonal antibody E7H2 
mutant TNF  molecules and their use for defining the epitope directed against human TNF-~, the region involved in the 
binding of this antibody includes sequence ValGluLeuArg in the recognized by Mabs E7H2. 
N-terminal part of the TNF-ot molecule. 
2. Materials and methods 
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(TNF-~); Hybrid proteins; Expression in E. coli; 2.1. Plasmids and strains 
Monoclonal antibody; Immunoblott ing The construction of a semisynthetic gene for human TNF-e~ (plas- 
mid pTNF331) adapted for bacterial expression has been reported 
[11]; plasmid pLT21 coding for shortened human lymphotoxin 
(TNF-~) [12], plasmid pTNF336 [13] with a mutated gene for TNF- 
1. Introduction e~ were previously described. Plasmid pmTNF harboring a gene for 
murine TNF-c~ under the control of a trp-promoter was kindly pro- 
The molecular basis of the exquisite specificity which is vided by Drs. V. Kravchenko and S. Nedospasov. E. coli strain 
characteristic for molecular ecognition between certain types SG20050 [14] was used for expression of the hybrid and mutant genes. 
of biomolecules still remains an important issue despite many 2.2. Construction ofplasmids 
studies in this field. The advent of gene cloning and engineer- General genetic engineering techniques were essentially performed 
ing of vectors for efficient expression made many recombinant as described in [15]. Enzymes were purchased from Fermentas 
proteins of biological interest available, followed by a break- (Lithuania). 
Plasmid pTNF331 was cleaved simultaneously with Mspl and 
through in the structural and functional analysis of bioactive HindIII, and a 504 bp fragment of the human TNF-c~ gene lacking 
proteins and cell receptors, including facilitated X-ray crystal- 32 N-terminal codons was purified by electrophoresis in 8% PAG and 
lographic studies of three-dimensional structure of these pro- then ligated with a HindIII-XhoI fragment (3.2 kbp) of pTNF331 in 
teins [1,2]. Monoclonal antibodies are essential tools for these the presence of excess of 5'-dephosphorylated synthetic 18 bp XhoI- 
MspI duplex. Screening of recombinant clones was carried out by in 
analyses. The functional regions of the protein of interest can situ hybridization with 5'-32P-labeled oligonucleotide insert. As a re- 
be identified by mapping the epitopes recognized by antibod- sult, plasmid pTNF90 containing the gene for human TNF-e~ with a 
ies which are capable of modulating biological activities and, deletion of 22 amino acid residues (7-28) in its N-terminal part was 
in particular, interact with the receptor protein and inhibit developed. 
Plasmids pTNFab and pTNFba, coding for hybrids between 
binding to the specific ligand [3]. hTNF-c~ and hTNF-[~, were developed by recombining plasmid 
Previously, mapping of antigenic determinants relied upon pTNF336, a derivative of pTNF331 containing a PstI restriction 
the analysis of panels of evolutionarily related proteins. Alter- site in the TNF-c~ gene, with pLT21. For this purpose, a vector pre- 
natively, epitopes were mapped using chemical modification pared by digestion of pTNF331 with KpnI and HindIII (3.2 kbp) was 
or protection of particular amino acid residues [4] or frag- ligated with a 402 bp KpnI-PstI fragment of pTNF336 and a 342 bp 
PstI-HindIII fragment of pLT21. The resulting plasmid was named 
ments purified by high-performance liquid chromatography pTNFab. Similarly, plasmid pTNFba was constructed by ligation of a 
after chemical or proteolytic cleavage of the entire antigen 3.4 kbp HindIII-KpnI vector with a 548 bp KpnI-PstI fragment of 
molecule [5,6]. pLT21 and a 223 bp PstI-HindIII fragment of pTNF336. 
Tumour necrosis factor (TNF-c~), a pleiotropic cytokine To construct in-frame fusions of the murine and human TNF-~ 
proteins, we took advantage of the presence of restriction cleavage 
sites common in both genes. For constructing plasmid pmhTNF36, a 
*Corresponding author. Fax: (7)(095)310-7007. 1072 bp PstI-BglI fragment of plasmid pmTNF was inserted into 
E-mail: korobko@ibch.siobc.ras.ru BglI-PstI sites of plasmid pTNF331. In detail, the PstI-BglI fragment 
of pmTNF together with a 492 bp BglI-HindIII fragment of pTNF331 
**Present address." Laboratoire d'endocrinologie d la reproduction, were ligated with HindIII-PstI vector (2.84 kbp) derived from 
Hopital Saint-Francois d'Assise, 10, rue de l'Espinay, Quebec pTNF331. Similarly, plasmid pmhTNF49 was constructed by ligation 
(Quebec), G1L 3L5, Canada. of a 1111 bp PstI-Eco64I fragment of pmTNF with 736 bp Eco64I- 
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NcoI and 2.2 kbp NcoI-PstI fragments of pTNF331. Alternatively, Plasmlds 
plasmid phmTNF36 was obtained by inserting a PstI-Bgll fragment pTNF331 I I 
into the corresponding pmTNF vector using the multicomponent li- 
gation as described above, pmTNF 
pLT21 I , , , , 1 
2.3. Purification procedures 
Human and murine TNF and the chimeric proteins were isolated as pTNF90 
fOllOWS. After growth for 24 h at 37°C, bacteria were harvested by 
centrifugation, resuspended in a buffer containing 20 mM Tris-HC1, :Nv,~ ~ t , . . . .  J 
pH 7.5, 200 mM NaC1, 0.1% mercaptoethanol and 10 gg/ml PMSF, :N~ . . . . . . . . . .  . . . . . . . . .  q t 
and disrupted by sonication. After centrifugation (15000 rpm, 15 
min), the supernatant was dialyzed against buffer A (50 mM sodium pmh~V36 t 
phosphate, pH 7.5, 0.1% mercaptoethanol, 10 gg/ml PMSF) and ap- phmTNF36 
plied to a hydroxyapatite column (Bio-Rad) equilibrated in the same 
buffer. Proteins were eluted with a linear sodium phosphate gradient pmhTNF49 ] 
(50--300 mM) in buffer A. Fractions were collected and analyzed for 
the presence of TNF-ct mutant and hybrid proteins by SDS-PAGE. {hot  M~gl Bgll Eco641 
Positive fractions were pooled, dialyzed against buffer B (20 mM Tris- Fig. 2. Schematic presentation of mutant and hybrid proteins. Open 
HCI, pH 7.5, 0.1% mercaptoethanol, 10 p.g/ml PMSF) and applied and filled bar segments represent murine and human TNF-tz coding 
onto a DEAE-Toyopearl 650 column (Toyo Soda) equilibrated in the information, respectively; crosshatched bar segments represent hu- 
same buffer. The target proteins were eluted with a linear NaC1 gra- man TNF-I3 coding sequence. At the bottom, restriction sites used 
dient (04).15 M) in buffer B. The fractions containing mutant TNF-tx to generate the chimeric proteins are shown. 
protein were pooled and sterilized by filtration through membrane 
filters (Millipore) with pore size 0.2 ~m. The protein concentration 
was determined by Protein assay kit II (Bio-Rad). filter was washed with 0.1% Tween-20 in TBS and then incubated with 
The monoclonal antibodies E7H2 were purified from hybridoma rabbit anti-mouse peroxidase-labeled immunoglobulin for 3 h at 20°C. 
supernatant or ascite fluid by affinity chromatography on antigen- The staining was performed by treatment with 4-chloronaphthol in 
Sepharose CL-4B. For this purpose, recombinant human TNF-ct TBS containing 20% methanol and 0.03% hydrogen peroxide. 
was immobilized on CNBr-activated Sepharose CL-4B (Pharmacia) 
according to standard procedure [16]. Ascite fluid was diluted 1:10 
with 50 mM potassium phosphate, pH 7.4, 0.5 M NaC1 and loaded on 
the immuunosorbent column equilibrated in the same buffer. The 3. Results and discussion 
column was carefully washed out, and Mabs E7H2 were eluted with 
glycine buffer, pH 2.8. The fractions containing Mabs E7H2 were Using previously prepared recombinant plasmids with arti- 
immediately neutralized with 1 M Tris, dialyzed against phosphate- ficial genes encoding wild-type human and mouse TNF-tx 
buffered saline, aliquoted and stored at -20°C. 
(pTNF331 and pmTNF,  respectively) as well as mutant 
2.4. Western blot analysis TNF-tx (pTNF336) and TNF-13 (pLT21), we developed a hu- 
SDS-electrophoresis in 13% PAG was performed in accordance man TNF-ct deletion gene and a number of in-frame chimeric 
with the procedure of Laemmli [17]. Immunoblotting with monoclo- genes encoding hybrids between human and mouse TNF-~ 
nal antibodies E7H2 was done essentially as described in [18]. Briefly, 
the transfer of proteins onto nitrocellulose membrane (Schleicher and human TNF-~x and TNF-~. For constructing a deletion 
&amp; Schuell) was carried out in an apparatus for semi-dry blotting variant of the human TNF-ct gene, we took advantage of the 
(BioTecMed) for 1 h at 0.8 mA/cm 2. Nonspeciflc protein binding was presence of a unique MspI  restriction site. Therefore, we re- 
blocked by the incubation of membranes in buffer TBS (10 mM Tris- placed in plasmid pTNF331 an 81 bp Xho I -Msp I  fragment 
HCI, pH 8.0, 150 mM NaCI) containing 1% BSA for 1 h at 20°C. with a short duplex (Fig. 1). As a result, plasmid pTNF90 
After overnight gentle shaking in a solution of E7H2, the membrane encoding human TNF-ct protein with deletion of amino acid 
residues 8-28 was made. The construction of genes encoding 
4 6 29  32  
. . .  aerSerArgLeuAsnArgArg. . ,  the hybrids between human tumour necrosis factor and lym- 
rGCAGCCC~CrGC,~CC,  photoxin was achieved by recombining plasmids pLT21 and 
CGGCrG~CrrGCGCG pTNF336. Since the plasmids each contain two Pst I  sites, the 
construction of pTNFba and pTNFab was done using three- 
component ligation as indicated in section 2. Plasmid 
pTNFab encodes a chimeric protein in which the amino 
acid sequence 3-125 of human TNF<t  is fused to the amino 
ecom ecoR~ acid sequence 125-171 of human lymphotoxin; plasmid 
Xhd EcoRl Kpnl 
XltoI pTNFba encodes a polypeptide sequence 22-125 of hTNF-13 
Bg~ B g ~  linked to sequence 127-157 of hTNF<z. 
Pstl Eco641 ~,,,t e~4~ For the construction of in-frame fusion genes encoding chi- 
meric human/mouse TNF-c~ protein, we took advantage of 
the presence of restriction sites, BglI  and Eco64I  common to 
both genes. Starting plasmids were pTNF331 and pmTNF 
H~dm ne,~m (Fig. 1), which were previously shown to direct efficient pro- 
Clal 
duction of human and murine TNF-ct, respectively. Depend- 
Fig. 1. Structure of synthetic duplex for construction of plasmid ing on the upstream coding sequence, mutant and chimeric 
pTNF90 and schematic map of plasmids pTNF331 and pmTNF for genes were expressed either under control of a tandem of two 
construction and expression of hybrid TNF-ct genes: htnfa and promoters A2 and A3 [19,20] from early region of bacterio- 
mtnfa, genes for human and murine TNF-ct, respectively; bla, E. phage T7 (in plasmids pTNF331, pLT21, pTNF90, pTNFab, 
coli 13-1actamase; PA2 and PAa, transcriptional promoters A2 and A3 
from early region of bacteriophage T7, respectively; Pt~, E. coli trp- pTNFba,  and phmTNF36) or E. coli t rp -promoters  (in plas- 
promoter, mids pmTNF,  pmhTNF36, and pmhTNF49). Notably, the 
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A g brid protein mhTNF36 was essentially weaker in comparison 
with wild-type protein or deletion variant TNF90. Probably 
there are amino acids located between residues 29 and 37 
12345678910 12345678910 which are not obligatory for formation of the binding site; 
however, the presence of these residues ignificantly facilitates 
• the interaction of these Mabs with the antigen. Besides, the 
location of the Mabs E7H2 binding site explains the failure of 
this antibody to neutralize a biological activity of hTNF-ct. In 
fact, Mabs E7H2 recognize the amino acid sequence located 
on the external surface of the TNF-~x trimer molecule within a 
short 13-pleated region which is not involved in interaction at 
least with the second type of TNF receptor (TNFR55) as was 
O Q:~:!i~ii~i,,~ ~ '~ shown by analysis of the crystal structure of the soluble hu- 
: l i ! !  N man 55 kDa TNF receptor-hTNF-[3 complex [1]. 
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